Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab

Bone

Volumn 56, Issue 2, 2013, Pages 482-488

  Genant, Harry K ^a,b   Libanati, Cesar ^c   Engelke, Klaus ^d,e   Zanchetta, Jose R ^f   Høiseth, Arne ^g   Yuen, Chui Kin ^h   Stonkus, Sigtas ⁱ   Bolognese, Michael A ^j   Franek, Edward ^k,l   Fuerst, Thomas ^b   Radcliffe, Hoi Shen ^m   McClung, Michael R ⁿ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SYNARC INC   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e Synarc Inc   (Germany)

^f Instituto de Investigaciones Metab licas   (Argentina)

^g SIGMA Canadian Menopause Society ^*  (Norway)

^h SIGMA Canadian Menopause Society   (Canada)

ⁱ KLAIPEDA UNIVERSITY   (Lithuania)

^j Bethesda Health Research   (United States)

^k CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^l MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^m AMGEN LTD   (United Kingdom)

ⁿ OREGON OSTEOPOROSIS CENTER   (United States)

more..

Author keywords

Bone mineral content; Bone mineral density; Denosumab; Hip; Osteoporosis; Quantitative computed tomography

Indexed keywords

DENOSUMAB; PLACEBO;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE STRENGTH; BONE TISSUE; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; FEMALE; HIP; HUMAN; MULTICENTER STUDY (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBCORTICAL BONE; TRABECULAR BONE;

BONE MINERAL CONTENT; BONE MINERAL DENSITY; DENOSUMAB; HIP; OSTEOPOROSIS; QUANTITATIVE COMPUTED TOMOGRAPHY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84882712081     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.07.011     Document Type: Article

References (36)

1. Bouxsein M.L. Technology insight: noninvasive assessment of bone strength in osteoporosis. Nat Clin Pract Rheumatol 2008, 4:310-318.
2. Genant H.K., Engelke K., Fuerst T., Gluer C.C., Grampp S., Harris S.T., et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996, 11:707-730.
3. Carballido-Gamio J., Harnish R., Saeed I., Streeper T., Sigurdsson S., Amin S., et al. Proximal femoral density distribution and structure in relation to age and hip fracture risk in women. J Bone Miner Res 2013, 28:537-546.
4. Christiansen B.A., Kopperdahl D.L., Kiel D.P., Keaveny T.M., Bouxsein M.L. Mechanical contributions of the cortical and trabecular compartments contribute to differences in age-related changes in vertebral body strength in men and women assessed by QCT-based finite element analysis. J Bone Miner Res 2011, 26:974-983.
5. Kim K.M., Brown J.K., Kim K.J., Choi H.S., Kim H.N., Rhee Y., et al. Differences in femoral neck geometry associated with age and ethnicity. Osteoporos Int 2011, 22:2165-2174.
6. Sornay-Rendu E., Cabrera-Bravo J.L., Boutroy S., Munoz F., Delmas P.D. Severity of vertebral fractures is associated with alterations of cortical architecture in postmenopausal women. J Bone Miner Res 2009, 24:737-743.
7. Ammann P., Rizzoli R. Bone strength and its determinants. Osteoporos Int 2003, 14(Suppl. 3):S13-S18.
8. Brandi M.L. Microarchitecture, the key to bone quality. Rheumatology (Oxford) 2009, 48(Suppl. 4):iv3-iv8.
9. Steiniche T., Christiansen P., Vesterby A., Hasling C., Ullerup R., Mosekilde L., et al. Marked changes in iliac crest bone structure in postmenopausal osteoporotic patients without any signs of disturbed bone remodeling or balance. Bone 1994, 15:73-79.
10. Tobias J.H. How do bisphosphonates prevent fractures?. Ann Rheum Dis 1997, 56:510-511.
11. Genant H.K., Cann C.E., Ettinger B., Gordan G.S., Kolb F.O., Reiser U., et al. Quantitative computed tomography for spinal mineral assessment: current status. J Comput Assist Tomogr 1985, 9:602-604.
12. Lacey D.L., Tan H.L., Lu J., Kaufman S., Van G., Qiu W., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000, 157:435-448.
13. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
14. Udagawa N., Takahashi N., Yasuda H., Mizuno A., Itoh K., Ueno Y., et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000, 141:3478-3484.
15. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95:3597-3602.
16. Baron R., Ferrari S., Russell R.G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011, 48:677-692.
17. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese P.T., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059-1066.
18. Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Wang H., Liu Y., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008, 93:2149-2157.
19. Brown J.P., Prince R.L., Deal C., Recker R.R., Kiel D.P., de Gregorio L.H., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24:153-161.
20. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
21. Lewiecki E.M., Miller P.D., McClung M.R., Cohen S.B., Bolognese M.A., Liu Y., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007, 22:1832-1841.
22. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.
23. Miller P.D., Bolognese M.A., Lewiecki E.M., McClung M.R., Ding B., Austin M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
24. Austin M., Yang Y.C., Vittinghoff E., Adami S., Boonen S., Bauer D.C., et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 2012, 27:687-693.
25. McClung M.R., Zanchetta J.R., Hoiseth A., Kendler D.L., Yuen C.K., Brown J.P., et al. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. J Clin Densitom 2013, 16:250-256.
26. Bousson V., Le Bras A., Roqueplan F., Kang Y., Mitton D., Kolta S., et al. Volumetric quantitative computed tomography of the proximal femur: relationships linking geometric and densitometric variables to bone strength. Role for compact bone. Osteoporos Int 2006, 17:855-864.
27. Kang Y., Engelke K., Kalender W.A. A new accurate and precise 3-D segmentation method for skeletal structures in volumetric CT data. IEEE Trans Med Imaging 2003, 22:586-598.
28. Donaldson L.J., Cook A., Thomson R.G. Incidence of fractures in a geographically defined population. J Epidemiol Community Health 1990, 44:241-245.
29. Kanis J.A., Johnell O., Oden A., Dawson A., De Laet C., Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989-995.
30. Poole K.E., Treece G.M., Ridgway G.R., Mayhew P.M., Borggrefe J., Gee A.H. Targeted regeneration of bone in the osteoporotic human femur. PLoS One 2011, 6:e16190.
31. Boonen S., Adachi J.D., Man Z., Cummings S.R., Lippuner K., Torring O., et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011, 96:1727-1736.
32. Genant H.K., Engelke K., Hanley D.A., Brown J.P., Omizo M., Bone H.G., et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010, 47:131-139.
33. Burghardt A.J., Kazakia G.J., Sode M., de Papp A.E., Link T.M., Majumdar S. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res 2010, 25:2558-2571.
34. Engelke K., Fuerst T., Dasic G., Davies R.Y., Genant H.K. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis. Bone 2010, 46:1626-1632.
35. Rizzoli R., Chapurlat R.D., Laroche J.M., Krieg M.A., Thomas T., Frieling I., et al. Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study. Osteoporos Int 2012, 23:305-315.
36. Keaveny T.M., McClung M., Genant H.K., Zanchetta J.R., Kendler D.L., Brown J.P., et al. Denosumab improves both femoral and vertebral strength in women with osteoporosis: results from the FREEDOM trial. J Bone Miner Res 2010, 25:S31.